SUMMARY: This comprehensive guide details pharmaceutical serialization, the global mandate for assigning unique identifiers to drug units to combat counterfeiting. It covers technical data structures, distinguishes serialization from aggregation and track-and-trace, and outlines the regulatory frameworks for key markets like the US, EU, and India. Finally, it presents a 5-level technical architecture for successful implementation.
Pharmaceutical serialization, the process of assigning a unique identifier to each saleable drug unit and tracking it through the supply chain, is now globally mandatory in response to drug safety and anti-counterfeiting concerns.
This comprehensive guide explains serialization fundamentals (including GTIN + serial + batch + expiry data structures), distinguishes serialization from aggregation/track & trace, and lays out the Global Regulatory Framework for key markets (US, EU, Russia, India, Brazil, Saudi Arabia, etc.).
It covers agencies, laws, approval pathways, timelines, dossier/labeling requirements, post-market obligations, GMP, import/export and clinical trial basics for each market. We include a recommended 5-level technical architecture (L1–L5) and discuss data exchange standards (EPCIS/GS1).
Pharmaceutical serialization means assigning a unique code to each saleable unit of medicine and printing it (usually as a 2D barcode) on the packaging. This code (often GS1 DataMatrix format) typically encodes the product’s Global Trade Item Number (GTIN) plus batch/lot, expiration date, and a randomized serial number.
For example, U.S. DSCSA law requires a product identifier that includes the National Drug Code (NDC) or GTIN, a unique serial number, lot number, and expiry date. Once each unit has a unique code, supply chain events (production, packaging, shipping, dispensing) can be recorded and traced.
Serialization alone is not simply “printing a barcode,” it triggers an entire traceability program. A complete serialization system involves code generation, line integration (print/vision/verification), aggregation (parent-child linking of pack → case → pallet), event data capture, and secure data exchange among supply chain partners. These steps enable regulators, manufacturers, and dispensers to verify authenticity and trace every pack back to its source.
Global health authorities have mandated serialization because it dramatically reduces risk from falsified or diverted medicines.
Substandard or counterfeit drugs remain a serious worldwide problem; the World Health Organization warns that a significant percentage of medicines in low-resource settings may be falsified. Traceability laws help ensure that every authorized drug can be distinguished from fakes.
For example, the U.S. DSCSA law and the EU Falsified Medicines Directive create legal obligations for serialization to protect patient safety. Compliance is also commercially mandatory: any company exporting medicines must meet the importing country’s traceability laws (e.g., Saudi Arabia, India, Russia, Brazil, Nigeria, etc.).
In effect, serialization has become a baseline requirement in regulated pharma markets, and companies without compliant systems risk losing market access.
Across global standards, a pharmaceutical pack’s unique identifier follows a common pattern:
Together, these form a “DataMatrix payload” as defined in ISO/IEC 16022 with GS1 FNC1, or a 2D/QR code. Most systems use GS1 AIs (01) for GTIN, (21) for serial, (10) for lot, and (17) for expiry.
For example, in the U.S. DSCSA, the “Product Identifier” requires NDC (which can be mapped to a GTIN) + serial + lot + expiry on every package. In practice, manufacturers often place the unique code on the secondary packaging (carton) and the corresponding code or link on the primary unit.
A best practice is to print both machine-readable DataMatrix and human-readable text for these fields, to allow manual inspection during recalls or audits.
It’s critical to distinguish these terms:
In short, serialization = unique identity; aggregation = building unit hierarchies; track-and-trace = sharing event data to track product provenance. All layers rely on strong master data (GLNs, GTINs, etc.) and common standards.
Proper implementation covers all three, and PharmaSecure offers integrated L1–L5 solutions to support them.
The global move toward mandatory serialization represents a fundamental shift in drug safety, requiring manufacturers to adopt interoperable digital systems that meet stringent regional reporting and verification laws.
The FDA enforces serialization via the Drug Supply Chain Security Act (DSCSA 2013). Prescription drug packages must bear a unique product identifier (NDC/GTIN + serial + lot + expiry) in a 2D code.
By law, a fully electronic track-and-trace system between trading partners is required (enhanced requirements phased in by Nov 2023, with an additional one-year “stabilization” period through Nov 2024).
Drug approvals use eCTD format; NDA goal timelines are ~10 months (standard) and 6 months (priority). Current Good Manufacturing Practices (21 CFR 210/211) and PV reports (21 CFR 314.80) still apply.
Under the EU Falsified Medicines Directive (Delegated Regulation 2016/161), most prescription packs must carry a GS1 DataMatrix containing GTIN, serial number, batch, expiry (plus a national code if required) and an anti-tamper seal.
This took effect Feb 9, 2019. Packs are verified against the European Medicines Verification System at dispensing. Centralized marketing authorizations (via EMA) follow a ~210-day evaluation (plus clock-stops).
EU labeling/PIL requirements are per Directive 2001/83/EC. Pharmacovigilance follows EMA’s GVP guidelines, and GMP is governed by EudraLex Vol. 4 (Annex 11 for computerized systems).
CDSCO regulations cover both domestic and export needs. Domestically, Schedule H2 (“Top 300 brands”) products must carry a barcode/QR with manufacturer, product, batch, license, Mfg/Exp dates (effective Aug 1, 2023).
For exports, DGFT’s iVEDA system requires uploading parent–child data for each export shipment. DGFT Public Notice 39 (Feb 2, 2024) extended the iVEDA deadline to Feb 1, 2025 (earlier PharmaSecure guidance had implied 2024).
Drug approval dossiers follow NDCTR 2019 CTD formats (90 working-day review for CTs). India adheres to the WHO IMDRF for GMP; PV (ADR reporting) is under the NDCTR regulations.
The Chestny ZNAK system (per Government Order 1556) mandates serialization of medicines. All traded drugs must carry a Crypto-protected GS1 DataMatrix (GTIN + serial + crypto-code). The Russian center (CRPT) reports and reconciles all production and movement events in a central MDLP database.
The MDLP launched for medicines in 2020. Marketing authorizations follow Eurasian Economic Union (EAEU) procedures (EAEU Decision 78/2016; ~210 days). Labels must include the DataMatrix.
Post-market, companies comply with Eurasian GMP and report safety (MoH/council guides).
Brazil’s National Medicines Control System (SNCM) was set up by Law 11.903/2009. ANVISA’s regulations (RDC 319/2019) implement mandatory serialization and aggregation for medicines via DataMatrix codes. Select product groups had phased rollout dates (ANVISA’s IN 100/2021 details these).
MAHs submit dossiers via Anvisa’s electronic system; review targets are 120 days for priority, 365 days for standard applications. Labeling must meet RDC 71/2009 standards. Good Manufacturing Practices follow Brazilian ordinances (e.g., RDC 16/2013).
Periodic Safety Update Reports (PSURs) and adverse-event reporting are required per ANVISA rules.
The SFDA enforces GS1-based serialization. All prescription drug packs must bear a GS1 DataMatrix (GTIN+serial+lot+expiry) and cases a GS1-128 code. The Drug Track & Trace System (RSD) went live in 2018.
Manufacturers and importers report serial code data to the SFDA portal. New drug applications use SFDA’s eCTD guidelines; reviews are generally targeted within 180–210 days. SFDA’s Barcoding Specifications and Good Pharmacovigilance Practice guidelines apply. GMP inspections align with Saudi Good Manufacturing rules.
The National Agency for Food and Drug Administration and Control (NAFDAC) operates a Mobile Authentication Service (MAS) using scratch-off codes on medicines for consumer verification. NAFDAC is moving towards full serialization (proposed via GS1 DataMatrix) and aggregation in compliance with the NAFDAC Act.
Product registration follows NAFDAC guidelines; post-market, MAHs must maintain PV per NAFDAC regulations. Pharmacies and importers work under NAFDAC’s controlled substances and import rules.
Bahrain’s NHRA requires GS1 standards for pharmaceutical labeling. Each pack must carry a GS1 2D barcode (GTIN+serial+lot+expiry) and shipments are tracked at higher packaging levels. The NHRA phased in traceability after 2019, aligning with GCC standards.
MA dossiers follow Gulf Health Organization requirements. Local GMP and PV regulations mirror WHO/ICH guidelines. Pharmacies scan the code upon dispensing under NHRA oversight.
Uzbekistan’s Ministry of Health introduced a national pharmacovigilance and traceability system (ADIU), with mandatory serialization of medicines. Packs must bear a 2D GS1-compatible code (likely GTIN+serial+batch+expiry).
The Universal Pharmaco-Vigilance System (2019) suggests Uzbekistan is building a centralized database. Drug registration (Ministry) will require digital labeling per EAEU guidelines.
Turkey’s İlaç Takip Sistemi (ITS) requires unit-level serialization on all pharmaceutical packages using GS1 DataMatrix (GTIN+serial+batch+expiry) since early 2010s. The system is linked to the Ministry of Health database for real-time tracking of shipments and dispenses. MAHs submit dossiers per Turkish MoH regulations (often aligned with EU standards). GMP and PV follow Turkish legislation (aligning with PIC/S/ICH).
Pharmaceutical serialization systems are structured into a five-level digital architecture (L1–L5) that connects packaging machines, plant systems, enterprise databases, and regulatory authorities into one unified track-and-trace ecosystem.
This layered approach ensures that every medicine pack receives a unique identity and can be tracked throughout the supply chain, enabling compliance with global regulations such as US DSCSA, EU FMD, Russia Chestny ZNAK, and India iVEDA.
Each level performs a distinct role, starting from physical code printing on packaging lines to secure exchange of serialized product data with regulatory authorities and supply chain partners.
Level 1 is the foundation of serialization and consists of the physical devices installed directly on packaging lines that apply and verify unique identification codes on pharmaceutical products. These devices include industrial printers, vision inspection systems, barcode scanners, label applicators, and automatic rejection systems that ensure only correctly printed packs move forward in production.
At this level, each saleable unit of medicine is marked with a GS1-compliant DataMatrix or QR code containing essential product information such as GTIN, batch number, expiry date, and serial number. Accuracy at this stage is critical because any printing or verification error can affect downstream traceability and compliance. Device-level serialization, therefore, ensures high-speed and high-precision marking of packaging materials while maintaining regulatory standards for print quality and data integrity.
PharmaSecure enables this level through TruTrak™ machine kits, which combine industrial printing, vision inspection, and rejection capabilities to ensure reliable code application and verification directly on packaging lines.
Level 2 manages serialization activities at the packaging line level and acts as the control layer connecting packaging equipment with higher-level systems. While Level 1 devices physically apply codes, Level 2 software ensures that the correct serial numbers are requested, applied, verified, and reconciled during production.
This layer coordinates communication between printers, scanners, cameras, and packaging controllers, ensuring that each unit receives a valid serial number and that defective or duplicate codes are automatically rejected. It also maintains line-level audit trails and ensures compliance with production workflows and batch requirements. Level 2 systems play a crucial role in maintaining data integrity by preventing duplication of serial numbers and ensuring synchronization with higher-level repositories.
PharmaSecure provides this functionality through psID® Imprint™, which connects directly with packaging line devices, manages serial number requests, verifies print quality, and reconciles production data in real time.
Level 3 operates at the manufacturing site level and coordinates serialization processes across multiple packaging lines within a facility. This level acts as the central control hub for plant-wide serialization activities by allocating serial numbers to packaging lines and maintaining consistent master data across the site.
A critical function at this level is aggregation, which creates parent-child relationships between packaging hierarchies such as unit, bundle, case, and pallet. Aggregation enables supply chain stakeholders to scan a single higher-level code (such as a case or pallet) and automatically identify all individual serialized units contained within it. This greatly improves supply chain efficiency, recall accuracy, and inventory visibility.
PharmaSecure supports this level through psID® Manage™ and psID® Aggregate™, which allocate serial numbers across the plant, establish packaging hierarchies, and maintain site-level audit trails for regulatory compliance.
Level 4 serves as the enterprise-wide serialization repository that manages serialized product data across multiple manufacturing plants, contract manufacturing organizations (CMOs), and distribution networks. It acts as the single source of truth for all serialization events generated across the organization.
At this level, serialized data is consolidated into a secure centralized database that integrates with enterprise IT systems such as ERP and warehouse management systems. This enables pharmaceutical companies to manage billions of serial numbers, standardize master data across global operations, and generate compliance reports for different regulatory markets. Enterprise-level serialization systems also provide analytics and insights that help companies improve operational efficiency and supply chain transparency.
PharmaSecure delivers this capability through psID® Repo™, a cloud-based repository that securely stores serialized data, integrates with enterprise systems such as SAP and Oracle, and enables enterprise-wide traceability and compliance management.
Level 5 represents the external network layer where serialization data is exchanged with regulatory authorities, distributors, wholesalers, pharmacies, and supply chain partners. This level ensures that serialized product information is communicated in standardized formats such as EPCIS to meet global compliance requirements.
At this stage, serialization data generated at manufacturing sites is transmitted to national and regional regulatory systems such as the US DSCSA network, EU EMVS hub, Russia Chestny ZNAK, and other global compliance platforms. Level 5 enables end-to-end visibility of product movement across the supply chain and supports verification of medicines at different distribution stages, helping prevent counterfeiting, diversion, and unauthorized distribution.
PharmaSecure supports this level through psID® Trail™ and psID® Repo™, which enable secure exchange of EPCIS events with regulators and supply chain partners, ensuring compliance with global serialization mandates.
Interoperable data exchange is the heart of modern serialization networks. The GS1 EPCIS standard (Electronic Product Code Information Services) defines how to share serialized event data (commission, pack, ship, receive, etc.) between systems.
EPCIS events encapsulate the “what-when-where-why” of each serialized item. For example, when a pack is shipped, an EPCIS “ObjectEvent” can be generated and sent to a trading partner or regulatory repository.
EPCIS uses standardized “Capture” and “Query” interfaces, and a Core Business Vocabulary (CBV) to define terms (like location, business step, etc.). The FDA DSCSA guidance explicitly endorses standards (like EPCIS/CBV) to achieve secure, electronic traceability.
Serialization yields numerous benefits beyond mere compliance:
Despite the benefits, serialization projects are complex and fraught with challenges:
Regulatory Divergence: Different markets have different code formats, scope, and data requirements. U.S. DSCSA emphasizes interoperable electronic trace data, while the EU FMD emphasizes on-pack verification at dispensing. Other countries (Russia’s MDLP, India’s portal, Brazil’s SNCM, etc.) each have unique rules. Harmonizing all these in one system is difficult. (For example, India’s export mandate was recently extended from 2024 to Feb 1, 2025, highlighting shifting deadlines.)
Data Volume and Accuracy: Serializing millions of units generates massive data. Maintaining clean GTIN/lot/serial databases, synchronizing product master across legacy ERPs, and ensuring 100% scanning accuracy on lines are non-trivial. Bad master data leads to trace gaps.
Line Integration Downtime: Upgrading production lines to print and verify 2D codes can disrupt manufacturing. Serialization printers and cameras must be validated, and reject flows must be tightly controlled. Automation skillsets and change control disciplines (e.g., FDA 21 CFR Part 11 and EU Annex 11 validation) are needed.
Aggregation Complexity: Properly scanning and storing parent–child relationships requires tight coordination. Mergers or repack operations can break aggregation. PharmaSecure notes their hardware “seamlessly integrates with ERP/WMS to create parent-child links” to address this.
Interoperability & Network: Building connections to trading partners and government systems is often the hardest part. DSCSA, for example, requires secure networks and agreed data standards. Any partner without EPCIS capability or who fails to maintain required systems can break the chain.
Change Management: New serialized processes affect multiple functions (manufacturing, QA, IT, regulatory). Organizations must retrain staff, update documentation (SOPs for code exception handling), and revise recall procedures to use serialization data.
Overcoming these challenges requires a robust compliance-ready architecture (see next section), proven change management, and often external expertise (consultants or technology vendors).
PharmaSecure is positioned as a turnkey provider for serialization and related services. Their psID Suite claims a modular, end-to-end approach that can be scaled to global mandates. Key solution highlights:
The psID software suite is designed around the L1–L5 model. For example, psID Manage handles code requests/allocations, print and reconcile workflows, and provides dashboards and audit trails. It supports GS1 standards and can incorporate third-party codes (e.g., GSI, SPC).
The suite also includes modules like Imprint, Aggregate, shipment logging, and psID Trail for track-and-trace visibility across partners. Hardware-wise, PharmaSecure’s TruTrak machines combine printers, scanners, and data systems in one rugged assembly.
They claim quick integration (with pre-built recipes) and minimal line downtime. The hardware is said to support speeds up to 90–150 packs/min and features like duplicate check, OCR/OCV, and serialization + aggregation in one pass.
(Note: any 21 CFR Part 11 claims about hardware control should be validated with actual implementation.)
The company emphasizes support for “current and changing mandates worldwide.” Their Global Compliance page lists supported markets (DSCSA, FMD, MDLP, Saudi RSD, Nigeria MAS, etc.).
In practice, this means configurable code formats, multilanguage interfaces, and deployment of hardware/software per regulatory scope. For a global manufacturer, this is critical: one system must serve US, EU, India, and other markets simultaneously.
Serialization platforms must integrate with ERP/MES/WMS. PSID Suite is said to work with leading ERP systems for posting serial numbers and reading back shipment data. It provides APIs and data exchange connectors (e.g., REST or file-based) so that when a pack is scanned out, the order fulfillment or logistics system is updated, and vice versa. This integration ensures master data (product, batch, GLNs) and events flow seamlessly without manual entry.
Looking ahead, we expect serialization to become even more integrated and intelligent. Key trends include:
Overall, serialization will continue evolving from a compliance requirement to an integral part of PharmaDigitization. Companies with modular L1–L5 systems (like PharmaSecure’s) and who embrace open standards (GS1/EPCIS) will be well-positioned. This guide’s workflow and data models should prepare companies for future extensions.
What is a GTIN vs NDC?
A Global Trade Item Number (GTIN) is a GS1 standard identification for trade items (products). In the U.S., an NDC can be mapped to a GTIN for serialization purposes.
Is aggregation required everywhere?
Some countries (Russia, Saudi Arabia, Nigeria) require aggregating packages into cases/pallets for traceability; others (DSCSA) do not legally require aggregation, though it is recommended. Check each market’s rules.
Why use GS1 standards?
GS1 standards (GTIN, AI data formats, EPCIS, etc.) ensure global interoperability. Many regulations explicitly expect GS1 or GS1-compatible formats, which future-proofs your system.
Do I need a central repository if I already share data with partners?
It depends. DSCSA favors a distributed model (no central repo, but authorized data exchange), whereas EU/others have central verification systems. In either case, your company needs an internal “Level 4” repository to manage data consistently before reporting.
What if a deadline changes?
Regulatory deadlines (e.g. India iVEDA date) do shift. We cited DGFT Public Notice 39/2023 extending to Feb 1, 2025. Always verify with the actual government notice before finalizing launch dates.
pharmasecure seo / May 18, 2026
pharmasecure seo / April 6, 2026
pharmasecure seo / March 23, 2026
PharmaSecure is a global track-and-trace, product authentication and consumer engagement company that has helped protect billions of packages through its technology-enabled solutions. Our proven serialization capabilities have enabled large pharmaceutical companies to meet different traceability requirements.
©2025, PharmaSecure Inc. All Rights Reserved.
